BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34530214)

  • 1. Survival impact of increasing time to IMRT initiation following induction chemotherapy in nasopharyngeal carcinoma: A propensity score-matched analysis.
    Zhou X; Xu T; Yang Y; Xing X; Shen C; Hu C
    Oral Oncol; 2021 Nov; 122():105506. PubMed ID: 34530214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
    Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
    Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
    He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X
    Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
    Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis.
    Chen YP; Mao YP; Zhang WN; Chen L; Tang LL; Li WF; Liu X; Zhou GQ; Guo R; Sun Y; Kang TB; Zeng MS; Ma J
    Oncotarget; 2016 Mar; 7(12):14973-82. PubMed ID: 26942870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.
    Chen J; Ding J; Xu Y; Hong H; Lin X; Xu M; Yan L; Xu T; Fei Z; Chen C
    J Geriatr Oncol; 2023 Nov; 14(8):101648. PubMed ID: 37897887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
    Luo Y; Qin Y; Lang J
    Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
    Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
    Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J
    Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score-matching studies.
    Li M; Zhang B; Chen Q; Zhang L; Mo X; Chen Z; Jin Z; Chen L; You J; Zhang S
    Head Neck; 2021 Jun; 43(6):1912-1927. PubMed ID: 33644916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
    Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of waiting time for radiotherapy after last induction chemotherapy on prognosis of locally advanced nasopharyngeal carcinoma.
    Zhu KX; Ding T; E YM; Yang HW; Wu RP; Liu RJ; Zhou LL; Fu WJ; Jiang MP; Wang XL
    Head Neck; 2024 May; 46(5):1189-1200. PubMed ID: 38366691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study.
    Zhang LN; Gao YH; Lan XW; Tang J; OuYang PY; Xie FY
    Oral Oncol; 2015 Oct; 51(10):950-6. PubMed ID: 26209065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy.
    Peng H; Chen L; Zhang J; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    J Cancer; 2017; 8(3):371-377. PubMed ID: 28261337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.